SCHEMBL25075495

SCHEMBL25075495

CC(C)C1CCN(C(=O)CCN2CC(C(C)C)C2)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.42
GNAI3 P08754 7/20 0.40
GNAO1 P09471 7/20 0.40
GNAI1 P63096 7/20 0.40
ELANE P08246 1/20 0.39
HSD11B1 P28845 1/20 0.38
POLB P06746 2/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
ALDH1A1 P00352 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CPN1 P15169 1/20 0.35
CPB2 Q96IY4 1/20 0.35
HTR1A P08908 1/20 0.35
HTR7 P34969 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25075107 0.92 NPC1 (0.41) NPC1GNAI3GNAO1GNAI1ELANE
SCHEMBL25075118 0.92 NPC1 (0.41) NPC1GNAI3GNAO1GNAI1ELANE
SCHEMBL26494345 0.92 NPC1 (0.41) NPC1GNAI3GNAO1GNAI1ELANE
SCHEMBL25075110 0.91 GNAI3 (0.41) NPC1GNAI3GNAO1GNAI1ELANE
SCHEMBL26494176 0.91 NPC1 (0.47) NPC1GNAI3GNAO1GNAI1HSD11B1
SCHEMBL26494075 0.90 NPC1 (0.44) NPC1GNAI3GNAO1GNAI1ELANE
SCHEMBL25075103 0.88 HSD11B1 (0.49) ELANEHSD11B1POLBMEN1KMT2A
SCHEMBL26494190 0.87 NPC1 (0.41) NPC1GNAI3GNAO1GNAI1ELANE
SCHEMBL2603233 0.86 ELANE (0.46) NPC1GNAI3GNAO1GNAI1ELANE
SCHEMBL25075307 0.85 NPC1 (0.53) NPC1GNAI3GNAO1GNAI1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. 2023-05-04 US disclosed
WO-2023023537-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. (US) 2023-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE BTK, BCL9, CRBN NPC1 4398/4885GNAI3 1728/4885GNAO1 3018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.